Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC.ACTU · Entity 7370 | Chief Financial Officer | April 01, 2026 | April 01, 2026 |
| Avid Bioservices, Inc.PPHM · Entity 83494 | Chief Financial Officer | April 28, 2017 | April 28, 2017 |
| Mosaic ImmunoEngineering Inc.CPMV · Entity 8636 | Director · EVP, Chief Financial Officer · 10% owner | January 29, 2021 | January 29, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACTUATE THERAPEUTICS, INC.
Report date April 01, 2026 · Filed April 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.49 · Expires 2036-04-01 | Direct | 105,000 |
Reported balance
After 2026-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-01 · Grant · Acquired 105,000 · Balance 105,000 F1: Options will vest as to 25% on April 1, 2027 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Options will vest as to 25% on April 1, 2027 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date.
Avid Bioservices, Inc.
Report date April 28, 2017 · Filed April 28, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 184,038 |
Reported balance
After 2017-04-28 transaction · row 1
1 source rowRow 1 · 2017-04-28 · Other · Acquired 37,389 · Balance 184,038 F1: Shares acquired under the issuer's employee stock purchase plan on April 28, 2017 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired under the issuer's employee stock purchase plan on April 28, 2017
Mosaic ImmunoEngineering Inc.
Report date January 29, 2021 · Filed January 29, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,641,252 |
Reported balance
After 2021-01-29 transaction · row 1
1 source rowRow 1 · 2021-01-29 · Conversion · Acquired 1,641,252 · Balance 1,641,252 F1: Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021. |
| Series A Convertible Voting Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-01-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-29 · Conversion · Disposed 161,000 · Balance 0 F1: Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021. F2: The Series A Convertible Voting Preferred Stock has no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021.
F2: The Series A Convertible Voting Preferred Stock has no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2026 Filed Apr 1, 2026 21:19 UTC | ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370 | GrantEmployee Stock Option (right to buy) · Derivative | 105,000 | $0.00 Strike: $2.49 | $0.00 |
DisclosureSEC source: 0001683168-26-002580 · ownership.xml · derivative · entry 1 LYTLE PAUL J · CIK 0001244110 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2036-04-01 F1 · derivative.exercise_date: Options will vest as to 25% on April 1, 2027 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 17:41 UTC | ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370 | GrantEmployee Stock Option (right to buy) · Derivative | 41,899 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001683168-25-002208 · ownership.xml · derivative · entry 2 LYTLE PAUL J · CIK 0001244110 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,899 Underlying: Common Stock · 41,899 shares Expires 2035-03-31 F2 · derivative.exercise_date: Options will vest as to 25% on August 14, 2025 with the remaining 75% vesting in equal monthly installments during the 36 months thereafter. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 17:41 UTC | ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370 | GrantEmployee Stock Option (right to buy) · Derivative | 49,394 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001683168-25-002208 · ownership.xml · derivative · entry 1 LYTLE PAUL J · CIK 0001244110 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,394 Underlying: Common Stock · 49,394 shares Expires 2035-03-31 F1 · derivative.exercise_date: Options will vest as to 25% on April 1, 2026 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date. Read SEC document |
| August 14, 2024 Filed Aug 14, 2024 23:28 UTC | ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370 | GrantNon-Qualified Stock Options · Derivative | 234,971 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001104659-24-089794 · tm2421559-4_4seq1.xml · derivative · entry 1 LYTLE PAUL J · CIK 0001244110 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 234,971 shares Expires 2034-08-14 F1 · derivative.exercise_date: 234,971 stock options granted upon the closing of the issuer's initial public offering on August 14, 2024, 25% of which vest on June 1, 2025 and the remaining 75% of which vest in equal monthly installments during the 36 months following June 1, 2025. Read SEC document |
| January 29, 2021 Filed Jan 29, 2021 22:32 UTC | Mosaic ImmunoEngineering Inc. CPMV · Entity 8636 | ConversionSeries A Convertible Voting Preferred Stock · Derivative | 161,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-21-000322 · ownership.xml · derivative · entry 2 LYTLE PAUL J · CIK 0001244110 · Director · EVP, Chief Financial Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,641,252 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021. F2 · derivative.exercise_price: The Series A Convertible Voting Preferred Stock has no expiration date. F1 · price: Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021. F1 · derivative.exercise_date: Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021. F2 · derivative.expiration_date: The Series A Convertible Voting Preferred Stock has no expiration date. Read SEC document |
| January 29, 2021 Filed Jan 29, 2021 22:32 UTC | Mosaic ImmunoEngineering Inc. CPMV · Entity 8636 | ConversionCommon Stock | 1,641,252 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-21-000322 · ownership.xml · nonDerivative · entry 1 LYTLE PAUL J · CIK 0001244110 · Director · EVP, Chief Financial Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,641,252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 01:18 UTC | Mosaic ImmunoEngineering Inc. PTSCD · Entity 8636 | GrantRestricted Stock Units · Derivative | 37,772 | $3.30 | $124,647.60 |
DisclosureSEC source: 0001683168-20-004324 · ownership.xml · derivative · entry 2 LYTLE PAUL J · CIK 0001244110 · Director · EVP, Chief Financial Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,164 Underlying: Common Stock · 37,772 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F3 · derivative.expiration_date: RSU's granted under the Mosaic ImmunoEngineering Inc. 2020 Omnibus Incentive Plan as a long-term incentive grant equal to 25% of reporting person's annual base salary. RSUs will vest 100% on August 31, 2022, subject to the reporting person's continuous service to the Issuer on such vesting date. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 01:18 UTC | Mosaic ImmunoEngineering Inc. PTSCD · Entity 8636 | GrantRestricted Stock Units · Derivative | 42,392 | $3.30 | $139,893.60 |
DisclosureSEC source: 0001683168-20-004324 · ownership.xml · derivative · entry 1 LYTLE PAUL J · CIK 0001244110 · Director · EVP, Chief Financial Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,392 Underlying: Common Stock · 42,392 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F2 · derivative.expiration_date: RSU's granted under the Mosaic ImmunoEngineering Inc. 2020 Omnibus Incentive Plan as part of the reporting person's annual base salary. RSUs will vest 100% on August 31, 2021, subject to the reporting person's continuous service to the Issuer on such vesting date. Read SEC document |
| April 28, 2017 Filed Apr 28, 2017 18:57 UTC | Avid Bioservices, Inc. PPHM · Entity 83494 | OtherCommon Stock | 37,389 | $0.27 | $10,139.90 |
DisclosureSEC source: 0001683168-17-001049 · lytle_f4.xml · nonDerivative · entry 1 LYTLE PAUL J · CIK 0001244110 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,038 F1 · kind: Shares acquired under the issuer's employee stock purchase plan on April 28, 2017 Read SEC document |
| October 31, 2016 Filed Nov 1, 2016 20:04 UTC | Avid Bioservices, Inc. PPHM · Entity 83494 | OtherCommon Stock | 33,783 | $0.29 | $9,675.45 |
DisclosureSEC source: 0001683168-16-000447 · lytle_f4.xml · nonDerivative · entry 1 LYTLE PAUL J · CIK 0001244110 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,649 F1 · kind: Shares acquired under the issuer's employee stock purchase plan on October 31, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.